

Network radiotherapy treatment protocol for Prostate and Seminal Vesicles

SECTION 1: Treatment options	
Hormones	
<p>Patients receiving C61-36.25(I)5 SABR or C61-62(I)20 should not receive hormones. Otherwise, ADT duration is determined by the disease risk:</p> <ul style="list-style-type: none"> • Intermediate risk prostate cancer – 6 months • High risk or locally advanced node negative prostate cancer - 2 years • Node positive prostate cancer – 2 years minimum • Metastatic prostate cancer – lifelong hormones 	
Radiotherapy	
<p>There must be a 3-month delay between surgery and radiotherapy for all patients who have undergone a TURP.</p>	
<i>Indications and intent</i>	<i>Regime, technique and RCR</i>
<p>C61-36.25(I)5 SABR, Radical Low and favourable-intermediate risk (NCCN) Low volume grade group 3 cancer acceptable As per <i>PACE B</i></p>	<ul style="list-style-type: none"> • 36.25 Gy in 5 fractions DAILY/ALTERNATE days over 1-2 weeks • SABR • V36.25 Gy to PTV at least 95% • V40 Gy to CTV at least 95% • <i>RCR2</i> deliver whole course within 21 days
<p>C61-62(I)20, Radical Low and favourable-intermediate risk (NCCN) not suitable for SABR Low volume grade group 3 cancer acceptable As per <i>Standard Arm PACE B</i></p>	<ul style="list-style-type: none"> • 62 Gy in 20 fractions DAILY over 4 weeks • VMAT • Median dose (D50%) of PTVp_62 • <i>RCR2</i> five missed fractions
<p>C61-60(I)20 Radical Any T, node negative disease No PSA limit As per <i>Pivotal boost Arm A – NCCC</i> only As per <i>Pivotal and CHHiP – JCUH</i> only</p>	<ul style="list-style-type: none"> • 60 Gy in 20 fractions DAILY over 4 weeks • VMAT • Median dose (D50%) of PTVp_60 • <i>RCR2</i> five missed fractions
<p>C61-60(I)20+N, Radical High risk node negative and node positive disease, no PSA limit As per <i>Pivotal Boost Arm B- or NRG guidance</i></p>	<ul style="list-style-type: none"> • 60 Gy in 20 fractions DAILY over 4 weeks <ul style="list-style-type: none"> ◦ +Elective Nodes: 44-47 Gy ◦ +Involved nodes: 50-60 Gy (location dependent) • VMAT • Median dose (D50%) of PTVp_60 • <i>RCR2</i> five missed fractions
<p>C61-62(I)20+N Radical High risk node negative and node positive disease. No PSA limit. Dose escalation option for unfavourable local disease in presence of mild LUTS.</p>	<ul style="list-style-type: none"> • 62 Gy in 20 fractions DAILY over 4 weeks <ul style="list-style-type: none"> ◦ +Elective Nodes: 44-47 Gy ◦ +Involved nodes: 50-60 Gy (location dependent) • VMAT • Median dose (D50%) of PTVp_62 • <i>RCR2</i> five missed fractions
<p>C61-62(I)20+H Radical High risk node negative disease. No PSA limit. Dose escalation option for unfavourable local disease in presence of mild LUTS.</p>	<ul style="list-style-type: none"> • 62 Gy in 20 fractions DAILY over 4 weeks • VMAT • Median dose (D50%) of PTVp_62 • <i>RCR2</i> five missed fractions

<p>C61-60(I)20+IsoMet, Radical As per <i>Pivotal boost Arm A</i> but including an isolated metastasis eg. pubic bone</p>	<ul style="list-style-type: none"> • 60 Gy in 20 fractions DAILY over 4 weeks <ul style="list-style-type: none"> ◦ +IsoMet: 60 Gy • VMAT • Median dose (D50%) of PTVp_60 • <i>RCR2</i> five missed fractions
<p>C61-60(I)20+IsoMet+N, Radical As per <i>Pivotal boost Arm A</i> but including isolated metastasis e.g. pubic bone and nodes</p>	<ul style="list-style-type: none"> • 60 Gy in 20 fractions DAILY over 4 weeks <ul style="list-style-type: none"> ◦ +IsoMet: 60 Gy ◦ +Elective Nodes: 44-47 Gy ◦ +Involved nodes: 50-60 Gy (location dependent) • VMAT • Median dose (D50%) of PTVp_60 • <i>RCR2</i> five missed fractions
<p>C61-46(I)23+N Radical Phase 2 boost to whole pelvis after HDR brachytherapy at Leeds Teaching Hospital</p>	<ul style="list-style-type: none"> • 46 Gy in 23 fractions DAILY over 4.5 weeks • VMAT • Median dose (D50%) of PTV • <i>RCR2</i> five missed fractions • Commence within 3 weeks
<p>C61-37.5(I)15 Radical Phase 2 boost to local disease after HDR brachytherapy at Leeds Teaching Hospital</p>	<ul style="list-style-type: none"> • 37.5 Gy in 15 fractions DAILY over 3 weeks • VMAT • Median dose (D50%) of PTV • <i>RCR2</i> five missed fractions • Commence within 3 weeks
<p>C61-36(I)6, Palliative Palliative/local control of locally advanced or low volume metastatic disease</p>	<ul style="list-style-type: none"> • 36 Gy in 6 fractions WEEKLY over 6 weeks • VMAT • Median dose (D50%) of PTV_36 • <i>RCR3</i> two missed fractions